Home › Compare › FTCHF vs ABBV
FTCHF yields 666666.67% · ABBV yields 3.12%● Live data
📍 FTCHF pulled ahead of the other in Year 1
Combined, FTCHF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of FTCHF + ABBV for your $10,000?
Farfetch Limited, together with its subsidiaries, operates a platform for the luxury fashion industry in the United States, the United Kingdom, and internationally. It operates through three segments: Digital Platform, Brand Platform, and In-Store. The company operates The Farfetch Marketplace, a global digital luxury fashion marketplace that connects consumers from approximately 190 countries and territories with merchandise from sellers, including brands, boutiques and department stores; New Guards, a platform that designs, manufactures, and distributes luxury fashion brands; Browns, a fashion and luxury goods retailer; Stadium Goods, a premium sneaker and streetwear marketplace and retailer; and VioletGrey.com, Luxclusif, Farfetch Future Retail, and other online sales channel. It also offers Farfetch Platform Solutions comprising building and operation of e-commerce and technology solutions for luxury brands and retailers; and ancillary services, including digital marketing, production, and customer services. In addition, the company operates Browns, Stadium Goods, Violet Grey, Off-White, Palm Angels, Ambush, and other brand stores; and Farfetch app. Further, the company engages in the web design, build, development, and retail distribution for retailers and brands. Farfetch Limited was founded in 2007 and is headquartered in London, the United Kingdom.
Full FTCHF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.